THE SIXTEENTH ANNUAL

Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Transformational Learning – EFFECTIVE KNOWLEDGE EXCHANGE





CO CHAIRS:



Matthew D'Ambrosio, MBA, JD, Senior Vice President, Chief Compliance and Ethics Officer, Sunovion Pharmaceuticals Inc.



Gary Del Vecchio, Executive Director, US Pharmaceutical Compliance and Ethics, Bristol-Myers Squibb Company



Elizabeth Jobes, Esq., Head of Corporate Compliance and Legal Counsel, Spark Therapeutics

KEYNOTE SPEAKERS:



Thomas W. Abrams, RPh, MBA, Director, Office of Prescription Drug Promotion, Food and Drug Administration



Robert Barrington, PhD, *Executive Director, Transparency International-UK*



Douglas Brown, Deputy Director, Data Sharing and Partnership Group, Center for Program Integrity, Centers for Medicare and

Medicaid Services, US Department of Health and Human Services

T

Benjamin C. Mizer, Esq., Principal Deputy Assistant Attorney General and Head of the Civil Division, US Department of Justice



Mary E. Riordan, Esq., Senior Counsel, Office of Counsel to the Inspector General, Office of Inspector

General, US Department of Health and Human Services



Jeffrey S. Sallet, National Chief of Public Corruption and Civil Rights, Federal Bureau of Investigation











пеанпанан

GOLD GRANTOR:

HuronLifeSciences

SILVER GRANTORS:









BRONZE GRANTORS:

































CONTINUING EDUCATION CREDITS:

Accounting Professionals: Approved for up to 16 NASBA CPE credits.

Compliance Professionals: The Congress is currently pending approval to offer Compliance Certification Board CCB Credits. **Attorneys:** The Congress is currently pending approval to offer California, Pennsylvania and Texas MCLE Credit.



October 21 – 23, 2015
Washington, DC Mandarin Oriental

SPONSOR:



PHARMACEUTICAL COMPLIANCE FORUM

SPECIAL PCF REGISTRATION DISCOUNTS — See page 11.



INVITATION TO ATTEND THE PCF PHARMA CONGRESS

As the new Vice President, Pharma and Medical Device Content, Global Health Care — Life Sciences, LLC, it is my pleasure to invite you to attend the 2015 Sixteenth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum sponsored by the PCF. This year's Congress will feature presentations by leading government regulators, company compliance professionals, in-house counsel, prominent industry consultants and legal counsel. Please plan to join me and the Planning Committee for three stimulating days of continuing education, networking and best practice sharing.

Precon IV: Advanced

Global Compliances Issues



Kelly B. Freeman, PhD, Vice President, Pharma and Medical Device Content, Global Health Care— Life Sciences, LLC; Former Senior Advisor, Ethics and Compliance, Eli Lilly and Company; Former Member, PCF Executive Committee, Indianapolis, IN

ABOUT THE CONGRESS SPONSOR

The Pharmaceutical Compliance Forum (PCF) is a coalition of senior compliance professionals and legal counsel from more than 50 of the largest research-based pharmaceutical manufacturers. The PCF was founded in early-1999 by compliance professionals from the pharmaceutical industry to promote effective corporate compliance programs. The members meet twice a year, for two days, focus-



ing on open and informal sharing of compliance information, best practices, and current developments in the field. PCF also sponsors this three-day compliance congress each Fall. For membership information, contact Kelly Freeman via email at kellfreem@gmail.com. Please visit their website at www.PharmaComplianceForum.org.

AGENDA AT A GLANCE

Wednesday, October 21, 2015

7:30 am **Congress Registration**

PRECONFERENCE SYMPOSIA (Optional, Choose only one): 8:00 am - 11:30 am

Precon I: Regulatory Precon III: Advanced Precon II: Innovations in

Concepts: Basic Principles Risk Assessment, Auditing Issues in Domestic and and Monitoring Global Transparency ...

OPENING PLENARY SESSION

1:00 pm Welcome and Introduction: PCF Co-Chairs

1:15 pm Keynote: OIG Update

AUSA Panel 2:00 pm

2:45 pm FBI's New Focus on FCPA Investigations

3:15 pm

Keynote: FDA-OPDP Update 3:45 pm

Chief Compliance Officer Roundtable 4:15 pm

5:00 pm Panel: FCPA Anticorruption: Examining a Hypothetical Case from All Sides: DOJ, SEC, and CCO

ADJOURNMENT AND NETWORKING RECEPTION 5:45 pm

Thursday, October 22, 2015

Registration Opens; Continental Breakfast in Exhibit Hall 7:00 am

MORNING PLENARY SESSION

8:00 am Welcome and Introductions 8:15 am US DOJ Civil Section Update

8:45 am Keynote: Transparency International's New Pharma Industry Initiative

9:15 am Qui Tam Panel

10:00 am Recent Developments in the Debate over Off-Label Communications and the First Amendment

10:30 am Networking Break

11:00 am - 12:00 pm MINI SUMMITS BLOCK A

MS I: Managing MS II: R&D MS III: Business MS IV: Evaluating MS V: Pavers and MS VI: Patient Speaker Program Compliance . . . Development Compliance Program Providers Part 1... **Support Programs** Compliance . . . Effectiveness . . . Part 1

12:00 pm NETWORKING LUNCHEON

1:15 pm - 2:15 pm MINI SUMMITS BLOCK B

MS VII: Predictive MS VIII: Coordinating MS IX: Managing MS X: Business MS XI: Impact of MS XII: Patient Analytics Risk Management . . . Multi-National HCP Development Part 2... Public Disclosures... **Support Programs** Meetings . . . Part 2 . . .

2:15 pm Transition Break

MINI SUMMITS BLOCK C 2:30 pm - 3:30 pm

MS XIII: MS XIV: MS XV: MS XVI: Business MS XVII: MS XVIII: MS XIX: Innovation in Compliance New Product Development Marketing and Structuring Spe-Payers and Providers Training and Considerations ... Launches . . . Part 3 . . . Medical Affairs . . . cialty Pharmacy Communications Distribution . . . Part 2 . . .

Networking Break 3:30 pm

CLOSING PLENARY SESSION

4:00 pm Update from CMS on Open Payments

Consolidation, Vertical Integration and Cross-Border Business 4:30 pm Millennials and the Future of Ethics and Compliance Programs 5:15 pm

6:30 pm Adjournment

Friday, October 23, 2015: INDUSTRY-ONLY COMPLIANCE BEST PRACTICES THINK TANK, 8:30 am - Noon

PARTICIPATION OPTIONS

TRADITIONAL ONSITE ATTENDANCE

Simply register, travel to the conference city and attend in person.

PROS: subject matter immersion; professional networking opportunities; faculty interaction.



Onsite

LIVE AND ARCHIVED INTERNET ATTENDANCE

Watch the conference in live streaming video over the Internet and at your convenience at any time 24/7 for six months following the event.

The archived conference includes speaker videos and coordinated PowerPoint presentations.

PROS: Live digital feed and 24/7 Internet access for the next six months; accessible in the office, at home or anywhere worldwide with Internet access; avoid travel expense and hassle; no time away from the office.



At your office . . .



. . . or home

WHO SHOULD ATTEND:

- Pharmaceutical and Health Care Executives and Board Members
- **Compliance Executives**
- Health Plan, Health System and Physician Organizations
- **Medical Directors**
- **Physicians**
- Pharmacists and Pharmacy Technicians
- Purchasers, including Private Employers and Public Purchasers
- Pharmaceutical Manufacturers
- **Generic Pharmaceutical Manufacturers**
- Site Management Organizations
- **Clinical Research Organizations**
- **Pharmacy Benefit Management Companies**
- Nurses
- Health Plans and Health Insurers
- Wholesale, Retail, Mail Order and Internet Pharmacies
- Health Care Attorneys and In-house Counsel
- **Compliance Officers**
- **Privacy Officers**
- **Ethics Officers**
- Food and Drug Law Attorneys
- **Pharmaceutical Consultants**
- **Investment Bankers**
- **Venture Capitalists**
- Health Care Regulators and Policy Makers
- **Health Services Researchers and Academics**
- **Auditors**

WEDNESDAY, OCTOBER 21, 2015

7:30 am **Congress Registration**

PRECONFERENCE SYMPOSIA (Optional, Choose only one)

Preconference I: Regulatory Concepts: Basic Principles

8:00 am



Welcome and Overview

James Gibney, Senior Director of Compliance, Regeneron Pharmaceuticals; Former Director, Worldwide Programs and US Investigations - Corporate Compliance, Pfizer, Tarrytown, NY (Moderator)

8:10 am



INDs, NDAs and Drug Development

Natasha Leskovsek, RN, MPM, MBA, JD, Health Care and Life Sciences Regulatory Practice, Cooley, LLP, Washington DC

8:40 am



Scientific Exchange

Saul Helman, MD, MBA, Managing Director and Life Sciences Practice Leader, Navigant Consulting, Inc., Indianapolis, IN

9:10 am



Patient Safety: Pharmacovigilance and REMS

Dr. Seth B. Whitelaw, President and and CEO, Whitelaw Compliance Group, LLC, West Chester, PA

9:30 am Break







Janet L. "Lucy" Rose, MBA, President, Lucy Rose and Associates, LLC; Former Director, DDMAC, FDA, Washington, DC

10:50 am



Promotion to Payers and Government Price Reporting

John Shakow, Esq., Partner, FDA and Life Sciences Practice, King & Spalding, Washington, DC

11:30 am

Preconference Adjournment

Preconference II: Innovations in Risk Assessment, Auditing and Monitoring

8:00 am



Welcome and Overview

Lori Alarimo, JD, Director, Healthcare and Life Sciences Disputes, Regulatory, Compliance and Investigations, Navigant Consulting, Inc., Irvine, CA (Moderator)

8:10 am



Incorporating Effective Record Reviews In Your Auditing & Monitoring Plan

Chris Castro, CCEP, Associate Director, Healthcare and Life Sciences Disputes, Regulatory, Compliance and Investigations, Navigant Consulting, Inc., Phoenix, AZ

8:50 am



Enhancing Sales Performance through Field Based Monitoring

Kerry Clem, Senior Vice President, Sales, Acorda Therapeutics, Ardsley, NY

Wendy Heckelman, PhD, President and Founder, WLH Consulting, Inc., Fort Lauderdale, FL



Break

9:45 am



Getting Ahead of the Game — Utilizing Data and **Other Operational Indicators to Identify Potential Compliance Issues Early**

Gary Keilty, Managing Director, FTI, Washington, DC



Daniel L. Dovdavany, Esq., Assistant General Counsel North America Litigation & Investigations, Sanofi US, Bridgewater, NJ

10:30 am



Building a Compliance Data Analytics Capability

Amy Pawloski, CPA, CCEP, Head of US Compliance & Ethics Monitoring and Data Analytics, Bristol-Myers Squibb, Plainsboro, NJ



Effective Field Monitoring Essentials to Consider when Working with Sales, **Marketing and Medical Teams**

Scot Steinheiser, CHC, CCEP, Managing Partner and Founder. Commercial Compliance Consulting, SCS Compliance Group LLC,

Gary Mendelson, Assistant Director, Corporate Compliance for Oncology, Astellas, Greer, SC

11:30 am

Preconference Adjournment

Preconference III: Advanced Issues in Domestic and Global Transparency and Analytics: Taking the Data to the Next Level

8:00 am



Welcome and Overview

Edward Glynn, MBA, Principal, Ernst & Young LLP, New York, NY (Moderator)

8:10 am



Exploring the Analytics Maturity Model: Capitalizing on your Investment in Aggregate Spend

Corey Dunbar, CFE, Senior Manager, Fraud Investigations & Dispute Services, Ernst & Young LLP, New York, NY

8:50 am



Linking Aggregate Spend Data with Other Data Sources to Identify Compliance Trends, **Learn about your Competitors and Provide** Strategic Insights to the Business

Véronique Monjardet , PhD, Country Manager — France, Polaris, Paris, France

9:30 am **Break**



Advanced Analytics: The Art of the Possible in Providing Value-Added Insights to the Business

Samir Hans, MS, Principal, Deloitte, Washington, DC

10:30 am



Using Company-specific and Open Payments Data to Ensure Accuracy and Gain Insights





Jonathan Wilkenfeld, MBA, President, Potomac River Partners, Vienna, VA

11:00 am



Growing and Integrating Global Transparency Analytics

Nadeem "Ned" Mumtaz, MBA, MIS, Practice Leader and Associate Partner, Streebo Inc., Princeton, NJ

Dr. Seth B. Whitelaw, President and CEO, Whitelaw Compliance Group, LLC, West Chester, PA



Preconference Adjournment

WEDNESDAY, OCTOBER 21, 2015 Preconferences, Continued from page 3

Preconference IV: Advanced Global Compliances Issues

8:00 am

Welcome and Overview



Nathaniel B. Edmonds, Esq., Partner, Paul Hastings; Former Assistant Chief, Foreign Corrupt Practices Act Unit, Fraud Section, Criminal Division, US Department of Justice, Washington, DC (Moderator)

8:10 am

Doing Business in China in 2016



David J. Ludlow, Esq., Partner, Sidley Austin, Washington, DC

8:40 am

Is Brazil the Next Hot Spot?



Esther M. Flesch, Esq., Partner, Trench, Rossi e Watanabe, A Baker McKenzie Affiliate, São Paulo, Brazil

9:10 am

Managing Compliance Risks Presented by Pharma Suppliers and Vendors: Beyond QRM and GMP



Traci Coughlan, Esq., Principal, Advisory Services, The Red Flag Group, Berlin, MD

9:40 am

Break



Applying Analytics to Compliance Programs Resulting in Informed Business Decisions



10:30 am

Monitoring and Auditing of Third Parties

Jeff Antoon, Director Internal Audit, Johnson & Johnson, New Brunswick, NJ

11:00 am

Application of Attorney-Client Privilege in the Context of Internal Cross-Border Bribery **Investigations**



Vivian Robinson, Esq., Queen's Counsel, Partner, McGuireWoods; Former General Counsel of the UK Serious Fraud Office; Former Head QEB Hollis Whiteman Chambers, Recorder of the Crown Court and Former Treasurer of Inner Temple, London, UK

11:30 am

Preconference Adjournment

WEDNESDAY, OCTOBER 21, 2015

PHARMA CONGRESS: AGENDA DAY I OPENING PLENARY SESSION

1:00 pm

Welcome and Introduction: PCF Co-Chairs



Matthew D'Ambrosio, JD, MBA, Senior Vice President, Chief Compliance and Ethics Officer, Sunovion Pharmaceuticals, Inc., Marlborough, MA (Co-chair)



Gary Del Vecchio, Executive Director, US Pharmaceutical Compliance and Ethics, Bristol-Myers Squibb Company, Plainsboro, NJ (Co-chair)



Elizabeth V. Jobes, Esq., Head of Corporate Compliance and Legal Counsel, Spark Therapeutics, Philadelphia, PA (Co-chair)

Keynote: OIG Update



Mary E. Riordan, Esq., Senior Counsel, Office of Counsel to the Inspector General, Office of Inspector General, Department of Health and Human Services, Washington, DC



Introduction by Matthew D'Ambrosio, JD, MBA, Senior Vice President, Chief Compliance and Ethics Officer, Sunovion Pharmaceuticals, Inc., Marlborough, MA (Co-chair)

2:00 pm





M. Beth Leahy, Esq. (Invited), Assistant US Attorney, United States Attorney's Office, Eastern District of Pennsylvania, Philadelphia, PA



Richard Robinson, Esq. (Invited), Section Chief-Major Frauds, Criminal Division, United States Attorney's Office, Central District of California, Los Angeles, CA



K. Nathaniel Yeager, Esq., Chief, Health Care Fraud Unit, United States Attorney's Office, District of Massachusetts, Boston, MA



John T. Bentivoglio, Esq., Partner, Skadden Arps LLP; Former Special Counsel for Healthcare Fraud and Chief Privacy Officer, US Department of Justice, Washington, DC (Moderator)

HOTEL INFORMATION/RESERVATIONS

The Mandarin Oriental is the official hotel for the SIXTEENTH PHARMACEUTICAL REGULATORY AND **COMPLIANCE CONGRESS.** A special group rate of \$300.00 Deluxe Room per night (plus tax) has been arranged for Congress Attendees.

To make your hotel reservations online please go to www.PharmaCongress.com and click on the Travel/ Hotel tab. You can also make reservations by calling the Mandarin Oriental directly at (202) 787-6140 or Toll Free (888) 888-1778. Please ask for the Pharma Congress Group Rate when you call.

Reservations at the group rate will be accepted while rooms are available or until the cut-off date of Tuesday, September 29, 2015. After this date, reservations will be accepted on a space-available basis at the prevailing rate.

The Pharmaceutical Compliance Congress does not contract with any third party organization to make hotel reservations for attendees of the Congress. All attendees should make their hotel reservations directly with the hotel and not with a third party vendor.

Mandarin Oriental • 1330 Maryland Avenue SW • Washington, DC 20024



2:45 pm

FBI's New Focus on FCPA Investigations

Jeffrey S. Sallet, National Chief of Public Corruption and Civil Rights, Federal Bureau of Investigation, Washington, DC



Introduction by Kris Curry, MBA, Principal, Fraud Investigation & Dispute Services, Ernst & Young LLP; Former Vice President, Health Care Compliance, Pharmaceuticals Group, Johnson & Johnson, Philadelphia, PA

3:15 pm

Break

Keynote: FDA-OPDP Update



Thomas W. Abrams, RPh, MBA, Director, Division of Drug Marketing, Advertising and Communications, Center for Drug Evaluation and Research (CDER), Food and Drug Administration, Silver Spring, MD



Introduction by Janet L. "Lucy" Rose, MBA, President, Lucy Rose and Associates, LLC; Former Director, DDMAC, FDA, Washington, DC





Melissa S. Barnes, Esq., Chief Ethics and Compliance Officer, Eli Lilly and Company, Indianapolis, IN



Tricia Glover, Vice President, US Chief Compliance Officer, Teva Pharmaceuticals, Kansas City, MO



Jonathon Kellerman, Executive Vice President, Global Chief Compliance Officer, Allergan PLC, Parsippany, NJ



Lawrence P. Platkin, Vice President and Head, U.S. Compliance Center of Excellence, Bayer Corporation, Whippany, NJ



Trudy Tan, CPA, Vice President Compliance International, AstraZeneca, Wilmington, DE



Erinn Hutchinson, Partner, Advisory Services, PwC, Philadelphia, PA (Moderator)

5:00 pm





Jeffrey H. Knox, Esq., Partner, Simpson Thacher; Former Chief, Fraud Section, Criminal Division, US Department of Justice, Washington, DC



Cheryl J. Scarboro, Esq., Partner, Simpson Thacher; Former Chief, FCPA Unit, US Securities and Exchange Commission, Washington, DC



Ashley Watson, Esq., Senior Vice President, Chief Ethics & Compliance Officer, Merck & Co, Inc., Former Counsel, Chief Ethics and Compliance Officer, Hewlett-Packard, Philadelphia, PA



Gary Giampetruzzi, Esq., Partner, Paul Hastings; Former Vice President and Assistant General Counsel, Head of Government Investigations, Pfizer Inc., Washington, DC (Moderator)

5:45 pm

ADJOURNMENT AND NETWORKING RECEPTION

THURSDAY, OCTOBER 22, 2015

PHARMA CONGRESS: AGENDA DAY II

7:00 am

Registration Opens; Continental Breakfast

MORNING PLENARY SESSION

8:00 am

Welcome and Introductions



Elizabeth V. Jobes, Esq., Head of Corporate Compliance and Legal Counsel, Spark Therapeutics, Philadelphia, PA (Co-chair)

US DOJ Civil Section Update



Benjamin Mizer, Esq., Principal Deputy Assistant Attorney General and Head of the Civil Division, US Department of Justice; Former Counselor to Attorney General Eric H. Holder, Jr., Washington, DC



Introduction by Michael K. Loucks, Esq., Partner, Skadden Arps LLP; Former Acting United States Attorney, US Attorney's Office for the District of Massachusetts, Washington, DC

8:45 am





Robert Barrington, PhD, Executive Director, Transparency International-UK, London, UK

Introduction by Jack Tanselle, MBA, Managing Director, Navigant Consulting, Inc., Indianapolis, IN

9:15 am

Qui Tam Panel



Jillian Estes, Esq., Partner, James Hoyer Newcomer & Smiljanich, PA; Former Attorney, International Division, National Center for Missing and Exploited Children, Tampa, FL



Loren Jacobson, Esq., Partner, Waters & Kraus LLP, Dallas, TX



Joseph Trautwein, Esq., Joseph Trautwein & Associates LLC; Former Assistant US Attorney, Eastern District of Pennsylvania, Philadelphia, PA



Jonathan Diesenhaus, Esq., Partner, Hogan Lovells LLP; Former Senior Trial Counsel, Fraud Section, Civil Division, US Department of Justice, Washington, DC (Moderator)

10:00 am

Recent Developments in the Debate over Off-Label Communications and the First Amendment



Paul E. Kalb, JD, MD, Partner and Global Coordinator, Life Sciences Practice, Sidley Austin LLP, Washington, DC



Introduction by Gary Del Vecchio, Executive Director, US Pharmaceutical Compliance and Ethics, Bristol-Myers Squibb Company, Plainsboro, NJ (Co-chair)

10:30 am

Networking Break

MINI SUMMITS BLOCK A 11:00 am - 12:00 pm

Mini Summit I: Managing Speaker Program Compliance: Benchmarking and Best Practices

Gregory Beeman, Lilly USA Ethics and Compliance Officer, Eli Lilly and Company, Indianapolis, IN

Ronni E. Fuchs, Esq., Partner, Pepper Hamilton LLP, Princeton, NJ

Raymond S. Wysmierski, MBA, MJP, Associate Director, Compliance, Avanir Pharmaceuticals, Inc., Aliso Viejo, CA

Katherine Buckley, MBA, Principal, Pharmaceutical and Life Sciences Advisory Practice, PwC, Philadelphia, PA (Moderator)

Mini Summit II: R&D Compliance: Prepare Now for Future Enforcement

Dennis K. Barnes, JD, MBA, CPA, Vice President, Chief Compliance Officer, PAREXEL International, Waltham, MA

Paul Curtin, JD, CFE, Executive Director, R&D Compliance, Allergan; Former Head of Compliance - Ex-US, Forest Laboratories, Jersey City, NJ

Daniel A. Kracov, Esq., Partner and Head, FDA and Healthcare Practice, Arnold & Porter, Washington, DC

George K. Ng, Esq., Executive Vice President & Chief Legal Officer, Sorrento Therapeutics, Inc., San Diego, CA

Yogesh Bahl, CPA, MBA, *Managing Director, Alix Partners, New York, NY (Moderator)*

Mini Summit III: Business Development Part 1: Mergers and Acquisitions — Preparing to be Acquired and Pre-Deal Due Diligence

Timothy Ayers, JD, MPH, Vice President, Chief Compliance Officer, Horizon Pharma plc; Former Vice President, Chief Compliance Officer, Dendreon, Chicago, IL

Justin Dillon, Senior Director - Compliance, Auditing & Monitoring, Incyte, Wilmington, DE **Michael B. Dusseau,** Vice President, Compliance Operations, Allergan plc; Former Vice President, Compliance, Bayer, Parsippany, NJ

William I. Intner, Esq., Partner, Hogan Lovells LLP, Baltimore, MD

Virginia "Ginny" A. Gibson, Esq., Partner, Hogan Lovells LLP; Former Executive Assistant U.S. Attorney, Eastern District of Pennsylvania, Philadelphia, PA (Moderator)

Mini Summit IV: Evaluating Compliance Program Effectiveness — Board Responsibilities, Board Advisors, and Compliance Experts

Thomas E. Costa, Esq., Compliance Consultant; Former Vice President, US Pharmaceuticals Compliance, Bristol-Myers Squibb, Yardley, PA

Christopher Fletchall, MBA, Senior Director, Ethics and Compliance, Eli Lilly and Company, Indianapolis, IN

Lawrence P. Platkin, Vice President and Head, U.S. Compliance Center of Excellence, Bayer Corporation, Whippany, NJ

Keith M. Korenchuk, JD, MPH, Partner, Arnold & Porter LLP, Washington, DC (Moderator)

Mini Summit V: Payers and Providers Part 1: Evolving Healthcare Systems and Promotional Interactions

Chris Cobourn, Managing Director, Huron Consulting Group, New York, NY

Alessandra Hawthorne, Esq., Vice President, Chief Ethics and Compliance Officer, Boehringer-Ingeheim Pharmaceuticals, Ridgefield, CT

Jeffrey Rosenbaum, MBA, Senior Vice President, Chief Compliance and Risk Officer, Shire; Former Chief Compliance Officer, Vertex Pharmaceuticals, Lexington, MA

Brian Riewerts, MPA, Partner, Global Pharmaceuticals and Life Sciences, PwC, Philadelphia, PA (Moderator)

Mini Summit VI: Patient Support Programs Part 1: Getting Closer to the Patient

Thomas M. Glavin, Esq., *Vice President, Deputy Compliance Officer, Shire, Philadelphia, PA* **Stephen M. Lawniczak, Esq.,** *Senior Counsel, AbbVie, Chicago, IL*

Alison Fethke, Esq., Counsel, Health Care Group, Ropes & Gray, Chicago, IL (Moderator)

12:00 pm NETWORKING LUNCHEON

MINI SUMMITS BLOCK B 1:15 pm - 2:15 pm

Mini Summit VII: Predictive Analytics

John Patrick Oroho, Esq., Executive Vice President and Chief Strategy Officer, Porzio Life Sciences, LLC; Principal, Porzio Bromberg & Newman, PC, Morristown, NJ

Mark Linver, MS, *Managing Director, Huron Consulting Group, New York, NY (Moderator)*

Mini Summit VIII: Coordinating Risk Management across the Control Functions: Audit, Compliance, Finance, Legal, Regulatory and Quality — An Opportunity to Leverage Technology

John Conrad, Principal, Deloitte, Philadelphia, PA

Mini Summit IX: Managing Multi-National HCP Meetings: Complying with the Codes and Transparency Requirements

Jodie Gillon, MPH (Invited), *Head, External Interface Office, AstraZeneca, New York, NY* **Tali Guy, Esq.,** *Senior Director, Global R&D Compliance Officer, Teva Pharmaceutical Industries Ltd., Petah Tikva, Israel*

Marc Eigner, MBA, MS, Senior Partner and Co-Founder, Polaris, New York, NY (Moderator)

Mini Summit X: Business Development Part 2: Mergers and Acquisitions — Post-Deal Due Diligence and Integration Challenges

Corey R. Amundson, Esq., First Assistant United States Attorney and Chief, Criminal Division, United States Attorney's Office, Middle District of Louisiana, Baton Rouge, LA

Jeffrey L. Handwerker, Esq., Partner, Arnold & Porter LLP, Washington, DC

Mark A. Jensen, Esq., Partner, Special Matters and Government Investigations Team, King & Spalding, Washington, DC

Joanne Lahner, Esq., Vice President, GHH Compliance, Merck & Co., Inc., North Wales, PA **Maureen McGirr, Esq.,** Vice President, Office of Ethics, Global Compliance Organization,
Merck & Co., Inc., Kenilworth, NJ (Moderator)

Mini Summit XI: The Impact of Public Disclosures on Operations and Processes within Life Science Organizations

Michael O'Connor, MS, Senior Director, Compliance and Ethics, Alexion Pharmaceuticals, Inc., Cheshire, CT

Gus Papandrikos, MBA, Senior Director, Compliance, Daiichi Sankyo, Parsippany, NJ **William Buzzeo, MS,** General Manager, US Compliance, IMS Health, Plymouth Meeting, PA (Moderator)

Mini Summit XII: Patient Support Programs Part 2: Patient Services: Privacy and Pharmacovigilance Considerations

William Greenrose, MA, MBA, *Director, Advisory - Governance Regulatory and Risk Strategies Practice, Deloitte & Touche, LLC, Boston, MA*

Megan Mikkelsen, CIPP/US, CHPS, Director, US Chief Privacy Officer, Teva Pharmaceuticals, Kansas City, MO

Terra L. Reynolds, Esq., Of Counsel, Litigation Department, Paul Hastings LLP; Former Assistant U.S. Attorney, Northern District of Illinois, Chicago, IL

Stephanie Wisdo, Esq., Corporate Attorney, Otsuka America Pharmaceutical, Inc., Princeton, NJ

Regina Gore Cavaliere, Esq., Principal, Advisory, KPMG; Former Vice President and Chief Compliance Officer, Otsuka America Pharmaceutical, Inc., Short Hills, NJ (Moderator)

2:15 pm Transition Break

EXHIBIT AND SPONSORSHIP OPPORTUNITIES

Take advantage of this unique opportunity to expand your reach! The Congress is attended by highly influential and experienced professionals. Sponsorship offers you strategic positioning as an industry leader. For more information call 206-673-4815 or email exhibits@hcconferences.com.

MINI SUMMITS BLOCK C 2:30 pm - 3:30 pm

Mini Summit XIII: Innovation in Training and Communications

Jayson Dukes, Senior Managing Director, FTI, New York, NY

Margaret K. Feltz, MA, JD, Executive Director, Corporate Compliance, Purdue Pharma LP; Former Member, PCF Executive Committee, Stamford, CT

Matthew Ruble, MS, Senior Manager, Grant Thornton, Philadelphia, PA (Moderator)

Mini Summit XIV: Compliance Considerations when Evaluating Non-Traditional HCP Compensation Arrangements: Royalties, Stock Options, and Licensing Agreements

Stuart A. Neiberg, MAcc, CPA, CFA, Director, HealthCare Appraisers, Delray Beach, FL Lee H. Rosebush, JD, PharmD, MS, MBA, Pharmacy Team Leader and FDA Partner, Baker & Hostetler LLP, Washington DC

Ann S. Brandt, PhD, Partner, HealthCare Appraisers, Inc., Delray Beach, FL (Moderator)

Mini Summit XV: New Product Launches and the Pre-Launch Period — Strengthening the Partnership with the Business

Terri Ledva, MS, Senior Manager Compliance, Iroko Pharmaceuticals LLC, Philadelphia, PA

Kari Loeser, Esq., Senior Counsel, Jazz Pharmaceuticals, Palo Alto, CA

Fernando Villegas, MS, Director, Oncology Marketing, Jazz Pharmaceuticals, Palo Alto, CA

Kelly N. "Nikki" Reeves, MPA, JD, Partner, King & Spalding LLP; Legal Counsel, Ad Hoc Sunshine and State Law Compliance Group, Washington, DC (Moderator)

Mini Summit XVI: Business Development Part 3: Joint Ventures and Co-Promotion Arrangements

Kathleen Hamill, Esq., Assistant General Counsel, Johnson & Johnson, Philadelphia, PA **Kellie Combs, Esq.,** Counsel, Ropes & Gray, Washington, DC (Moderator)

Mini Summit XVII: Marketing and Medical Affairs: Where is the Line in the Sand?

Mark A. DeWyngaert, MBA, PhD, Managing Director, Huron Consulting Group, New York, NY

Mini Summit XVIII: Structuring Specialty Pharmacy Distribution Arrangements in a Turbulent Regulatory Environment

Thomas Beimers, Esq., Healthcare, Compliance, and Government Investigations Attorney at Faegre Baker Daniels LLP, Minneapolis, MN

John "Jack" S. Linehan, Esq., Healthcare Attorney, Epstein Becker & Green, Washington, DC (Moderator)

Mini Summit XIX: Payers and Providers Part 2: Value Propositions in Contractual Relationships — Real World Evidence, **Outcomes Research, and Comparative Effectiveness**

Kathleen Peterson, Esq., Special Counsel, Cooley LLP, Washington, DC

BJ D'Avella, MBA, Senior Director, Huron Consulting Group, New York, NY (Moderator)

3:30 pm **Networking Break**

CLOSING PLENARY SESSION

4:00 pm

Update from CMS on Open Payments



Douglas Brown, Deputy Director, Data Sharing & Partnership Group, Center for Program Integrity, Centers for Medicare and Medicaid Services, US Department of Health and Human Services, Baltimore, MD



Introduction by Paul Silver, *Practice Leader and Managing Director,* Huron Consulting Group, Atlanta, GA

4:30 pm



Consolidation, Vertical Integration and Cross-Border Business: Confronting "Next Generation" Compliance Priorities

Barbara Rowland, Esq., Principal, Internal Investigations and White Collar Defense Group, Post & Schell, PC, Washington, DC

Kris Curry, MBA, Principal, Fraud Investigation & Dispute Services, Ernst & Young LLP; Former Vice President, Health Care Compliance, Pharmaceuticals Group, Johnson & Johnson, Philadelphia, PA (Moderator)



Millennials and the Future of Ethics and **Compliance Programs: New Technologies** and Eternal Issues



Professor Ann E. Tenbrunsel, *Author of Blind Spots: Why We Fail to* Do What's Right, and What We Can Do about It (with Max Bazerman); David E. Gallo Professor of Business Ethics, University of Notre Dame; Rex and Alice A. Martin Research Director of the Institute for Ethical Business Worldwide, Notre Dame, IN



Sujata Dayal, Esq., Vice President Health Care Compliance and Privacy, Pharmaceuticals, Johnson & Johnson; Former Global Chief Compliance Officer and Corporate Vice President, Biomet, Inc., Former Member PCF Executive Committee, Chicago, IL



Amy O'Connor, MPP (Invited), Senior Director, Digital and Social Media Communications, Eli Lilly and Company, Indianapolis, IN

Jeremy Perisho, Partner and US FAS Leader, Life Sciences & Health Care, Deloitte Financial Advisory Services LLP, Boston, MA (Moderator)

6:30 pm

Adjournment

FRIDAY, OCTOBER 23, 2015

PHARMA CONGRESS: AGENDA DAY III

INDUSTRY-ONLY COMPLIANCE (Industry-only session for pharmaceutical BEST PRACTICES THINK TANK in-house counsel only)

company compliance professionals and

8:30 am



Introduction to Day Three

Matthew D'Ambrosio, JD, MBA, Senior Vice President, Chief Compliance and Ethics Officer, Sunovion Pharmaceuticals, Inc., Marlborough, MA (Co-chair)



Gary Del Vecchio, Executive Director, US Pharmaceutical Compliance and Ethics, Bristol-Myers Squibb Company, Plainsboro, NJ (Co-chair)



Elizabeth V. Jobes, Esq., Head of Corporate Counsel and Legal Counsel, Spark Therapeutics, Philadelphia, PA (Co-chair)

Including an Update from PhRMA



Jeff Francer, Esq., Vice President and Senior Counsel, PhRMA; Former Associate Chief Counsel, Food and Drug Administration, Washington, DC



Lauren K. Roth, Esq., Assistant General Counsel, PhRMA, Washington, DC

Noon

CONGRESS ADJOURNMENT

ATTENDANCE OF CLOSED SESSION LIMITED

As noted above, attendance in the closed session is limited to company compliance professionals and in-house counsel only. The purpose of the closed session is to permit the attendees to engage in a more focused exchange of views regarding issue priority and best compliance practices. Upon registration, attendees will indicate if they plan to attend the closed session. If there is a question raised regarding qualification to attend the closed session, a member of the Congress planning committee will make the final determination.

2015 PCF PHARMA CONGRESS PLANNING COMMITTEE

Matthew D'Ambrosio, JD, MBA, Senior Vice President, Chief Compliance and Ethics Officer, Sunovion Pharmaceuticals, Inc., Marlborough, MA (Co-chair)

Gary Del Vecchio, Executive Director, US Pharmaceutical Compliance and Ethics, Bristol-Myers Squibb, Plainsboro, NJ (Co-chair)

Elizabeth V. Jobes, Esq., Head of Corporate Compliance and Legal Counsel, Spark Therapeutics, Philadelphia, PA (Co-chair)

Timothy Ayers, JD, MPH, Vice President, Chief Compliance Officer, Horizon Pharma plc, Chicago, IL

Scott Bass, Esq., Partner and Head, Global Life Sciences Team, Sidley Austin LLP, Washington, DC

John T. Bentivoglio, Esq., *Partner, Skadden Arps LLP, Washington, DC*

Yogesh Bahl, CPA, MBA, *Managing Director, AlixPartners, New York. NY*

Andy Bender, MS, MBA, President and Founder, Polaris, New York, NY

Mary Bradley, PharmD, Healthcare Compliance Officer, Johnson & Johnson, Philadelphia, PA

Eve Costopoulos, Esq., Former Vice President and Chief Ethics and Compliance Officer, Eisai Inc., Woodcliff Lake, NJ

Kris Curry, MBA, Principal, Fraud Investigation & Dispute Services, Ernst & Young LLP, Philadelphia, PA

Clive Davis, MA, JD, Vice President, Chief Compliance Officer, UCB Pharma, Atlanta, GA

Michael B. Dusseau, Vice President, Compliance Operations, Allergan plc, Parsippany, NJ

Margaret K. Feltz, MA, JD, Executive Director, Corporate Compliance, Purdue Pharma LP, Stamford, CT

Alison Fethke, Esq., Counsel, Health Care Group, Ropes & Gray, Chicago, IL

Jeffrey Fleming, Esq., Vice President Compliance North America and US Compliance Officer, AstraZeneca Pharmaceuticals LP, Wilmington, DE

Thomas M. Glavin, *Vice President, Head of Compliance – US, Shire, Wayne, PA*

Gary F. Giampetruzzi, Esq., Partner, Paul Hastings, New York, NY

Virginia "Ginny" A. Gibson, Esq., *Partner, Hogan Lovells LLP, Philadelphia, PA*

Wendy C. Goldstein, Esq., Partner, Health Care and Life Sciences Regulatory Practice, Cooley, LLP, New York, NY

Steven Guymon, Senior Compliance Advisor, Eli Lilly and Company, Indianapolis, IN

Alessandra Hawthorne, Esq., Vice President, Chief Ethics and Compliance Officer, Boehringer-Ingelheim Pharmaceuticals, Ridgefield, CT

Wendy Heckelman, PhD, President and Founder, WLH Consulting, Inc., Fort Lauderdale, FL

Erinn Hutchinson, *Partner, Advisory Services, PwC, Philadelphia, PA*

Margaret Jackson, MS, National Industry Marketing Director, Grant Thornton LLP, Raleigh, NC

Michael Joachim, Esq., Head of Global Corporate Compliance, Genzyme, a Sanofi Company, Cambridge, MA

Jeffrey S. Klimaski, MBA, CPA, Vice President, Global Ethics and Compliance Officer, BTG International Inc., Philadelphia, PA

Daniel A. Kracov, Esq., Partner and Head, FDA and Healthcare Practice, Arnold & Porter, Washington, DC

Terri Ledva, MS, Ethics & Compliance Leader, Iroko Pharmaceuticals, Philadelphia, PA

Beth Levine, Esq., Vice President, Associate General Counsel, Chief Compliance Officer, Regeneron, New York, NY

Christine Longawa, MA, CPA, CFE, Life Sciences Disputes, Compliance & Investigations Associate Director, Navigant Consulting, Chicago, IL

Maureen McGirr, Esq., Vice President Office of Ethics, Global Compliance Organization, Merck & Co., Inc., Philadelphia, PA

Maxine Nogard, Compliance Director, Biogen Idec, Weston, MA

John Patrick Oroho, Esq., Executive Vice President and Chief Strategy Officer, Porzio Life Sciences, LLC, Principal, Porzio, Bromberg & Newman PC, Morristown, NJ

Jeremy Perisho, Partner and US FAS Leader, Life Sciences & Health Care, Deloitte Financial Advisory Services LLP, Boston, MA

Lori Queisser, Senior Vice President and Global Chief Compliance Officer, Teva Pharmaceuticals, Horsham, PA

Kelly N. "Nikki" Reeves, MPA, JD, Partner, King & Spalding LLP, Washington, DC

Jeffrey Rosenbaum, MBA, Senior Vice President, Chief Compliance and Risk Officer, Shire; Former Chief Compliance Officer, Vertex Pharmaceuticals, Lexington, MA

Michael Shaw, Esq., Vice President and Compliance Officer, North America Pharmaceuticals & Global Franchises, GlaxoSmithKline, Philadelphia, PA

Glenna Shen, Esq., Head of Compliance, Onyx Pharmaceuticals, South San Francisco, CA


Paul Silver, Practice Leader and Managing Director, Huron Consulting Group, Atlanta, GA

David Vance, Esq., Senior Director Business Conduct, Noven Pharmaceuticals, Inc., Miami, FL

Dr. Seth B. Whitelaw, *President and CEO, Whitelaw Compliance Group, LLC, West Chester, PA*

Raymond Wysmierski, MBA, MJP, Associate Director, Compliance, Avanir Pharmaceuticals, Aliso Viejo, CA

2015/2016 GLOBAL PHARMA COMPLIANCE CONGRESSES



SAVE THE DATE! TENTH INTERNATIONAL PHARMACEUTICAL COMPLIANCE CONGRESS



...And Plan to Attend the SIXTH ASIA PACIFIC PHARMACEUTICAL COMPLIANCE CONGRESS AND BEST PRACTICES FORUM

Fall 2016 Watch for Details

Watch for Details at www.AsianPharmaCongress.com

THE FOLLOWING REGISTRATION TERMS AND CONDITIONS APPLY

REGARDING WEBCAST REGISTRATIONS

- 1. Individuals or groups may register for Internet access. Organizations may register for group access without presenting specific registrant names. In such instances the registering organization will be presented a series of user names and passwords to distribute to participants.
- 2. Each registrant will receive a user name and password for access. Registrants will be able to change their user names and passwords and manage their accounts.
- 3. Internet registrants will enjoy six (6) months access from date of issuance of user name and password.
- 4. Only one user (per user name and password) may view or access archived conference. It is not permissible to share user name and password with third parties. Should Internet registrants choose to access post conference content via Flash Drive, this individual use limitation applies. It is not permissible to share alternative media with third parties.
- 5. User name and password use will be monitored to assure compliance.
- 6. Each Internet registration is subject to a "bandwidth" or capacity use cap of 5 gb per user per month. When this capacity use cap is hit, the registration lapses. Said registration will be again made available at the start of the next month so long as the registration period has not lapsed and is subject to the same capacity cap.
- 7. For webcast registrants there will be no refunds for cancellations. Please call the Conference Office at 800-503-7419 or 206-452-5662 for further information.

REGARDING ONSITE ATTENDANCE REGISTRATION, CANCELLATIONS AND SUBSTITUTIONS

- For onsite group registrations, full registration and credit card information is required for each registrant. List all members of groups registering concurrently on fax or scanned cover sheet.
- 2. For onsite registrants there will be no refunds for "no-shows" or for cancellations. You may send a substitute or switch to the webcast option. Please call the Conference Office at 800-503-7419 or 206-452-5662 for further information.

METHOD OF PAYMENT FOR TUITION

Make payment to Health Care Conference Administrators LLC by check, MasterCard, Visa or American Express. Credit card charges will be listed on your statement as payment to HealthCare (HC) Conf LLC. Checks or money orders should be made payable to Health Care Conference Administrators LLC. A \$30 fee will be charged on any returned checks.

REGISTRATION OPTIONS

Registration may be made online or via mail, fax or scan.

You may register through either of the following:

- Online at www.PharmaCongress.com.
- Fax/Mail/Email using this printed registration form. Mail the completed form with payment to the Conference registrar at 22529 39th Ave. SE, Bothell, WA 98021, or fax the completed form to 206-319-5303, or scan and email the completed form to registration@hcconferences.com. Checks or money orders should be made payable to Health Care Conference Administrators LLC.

The following credit cards are accepted: American Express, Visa or MasterCard. Credit card charges will be listed on your statement as payment to HealthCare (HC) Conf LLC.

For registrants awaiting company check or money order, a credit card number must be given to hold registration. If payment is not received by seven days prior to the Congress, credit card payment will be processed.

TAX DEDUCTIBILITY

Expenses of training including tuition, travel, lodging and meals, incurred to maintain or improve skills in your profession may be tax deductible. Consult your tax advisor. Federal Tax ID: 91-1892021.

CANCELLATIONS/SUBSTITUTIONS

No refunds will be given for "no-shows" or for cancellations of either webcast or onsite registrations. You may send a substitute or transfer your onsite registration to an webcast registration. For more information, please call the Conference Office at 800-503-7419 or 206-452-5662.

INTELLECTUAL PROPERTY POLICY

Unauthorized sharing of Congress content via Internet access through the sharing of user names and passwords or via alternative media (Flash Drive) through the sharing of said media is restricted by law and may subject the copyright infringer to substantial civil damages. The Congress aggressively pursues

HOW TO REGISTER: Fully complete the form on page 11 (one form per registrant, photocopies acceptable). Payment must accompany each registration (U.S. funds, payable to Health Care Conference Administrators, LLC).

ONLINE: Secure online registration at www.PharmaCongress.com.

FAX: 206-319-5303 (include credit card information with registration)

MAIL: Conference Office, 22529 39th Ave SE, Bothell, WA 98021

FOR REGISTRATION QUESTIONS:

PHONE: 800-503-7419 (Continental US, Alaska and Hawaii only) or 206-452-5662, Monday-Friday, 7 AM - 5 PM PST

E-MAIL: registration@hcconferences.com

PHARMA CONGRESS CONTINUING EDUCATION CREDITS

NASBA CPE CREDIT

Health Care Conference Administrators, LLC is registered with the National Association of State Boards of Accountancy (NASBA) as a sponsor of continuing professional education on the National Registry of CPE Sponsors. State boards of accountancy have final authority on the acceptance of individual courses for CPE credit. Complaints regarding registered sponsors may be submitted to the National Registry of CPE Sponsors through its website: www.learningmarket.org.

A recommended maximum of 17.5 credits based on a 50-minute hour will be granted for the entire learning activity. This program addresses topics that are of a current concern in the compliance environment. This is an update, group-live activity. For more information regarding administrative policies such as complaints or refunds, call 206-757-8053 or petergrant@dwt.com.

COMPLIANCE CERTIFICATION BOARD CONTINUING EDUCATION UNITS (CCB CEUs)

The Congress is currently pending approval to offer Compliance Certification Board CCB Credits.

PENDING CONTINUING EDUCATION CREDITS

The Congress is currently pending approval to offer California, Pennsylvania and Texas MCLE Credit.

CERTIFICATE OF ATTENDANCE

Onsite attendees can request a Certificate of Attendance which they can file with appropriate entities for credit, and webcast attendees can request an Online Certificate of Attendance on which they can certify the number of hours they watched and can file with appropriate entities for credit.

copyright infringers. If a registrant needs the ability to share Congress content within his or her organization, multiple Congress registrations are available at discounted rates.

The Congress will pay a reward for information regarding unauthorized sharing of Congress content. The reward will be one quarter (25%) of any recovery resulting from a copyright infringement (less legal fees and other expenses related to the recovery) up to a maximum reward payment of \$25,000. The payment will be made to the individual or individuals who in the opinion of our legal counsel first provided the factual information, which was necessary for the recovery. If you have knowledge regarding the unauthorized Congress content sharing, contact the Congress registration office.

REGISTRATION BINDING AGREEMENT

Registration (whether online or by this form) constitutes a contract and all of these terms and conditions are binding on the parties. In particular, these terms and conditions shall apply in the case of any credit/debit card dispute.

GENERAL TERMS AND CONDITIONS

Program subject to cancellation or change. If the program is cancelled the only liability of the Congress will be to refund the registration fee paid. The Congress shall have no liability regarding travel or other costs. Registration form submitted via fax, mail, email or online constitutes binding agreement between the parties.

FOR FURTHER INFORMATION

Call 800-503-7419 (Continental US, Alaska and Hawaii only) or 206-452-5662, send e-mail to registration@hcconferences.com, or visit our website at www.PharmaCongress.com.

PHARMACEUTICAL CONGRESS

ATTENDANCE OF CLOSED SESSION LIMITED: As noted on page 7, attendance in the closed session is limited to company compliance professionals and in-house counsel only. The purpose of the closed session is to permit the attendees to engage in a more focused exchange of views regarding issue priority and best compliance practices. Upon registration, attendees will indicate if they plan to attend the closed session. If there is a question raised regarding qualification to attend the closed session, a member of the Congress planning committee will make the final determination.

COMPLETE THE FO	LLOWING. PLEASE P	RINT CLEARLY:		ADDRESS				
				ADDRESS				
NAME				CITY/STATE/ZIP				
SIGNATURE OF REGISTRANT - REQUIRED			TELEPHONE					
JOB TITLE				E-MAIL				
ORGANIZATION				☐ Special Needs (Dietary or Physical)				
ONSITE CONFERENCE ATTENDANCE				WEBCAST CONFER	ENCE ATT	ENDANCE		
STANDARD RATES: PRECONFERENCES (Choose one): 1: Regulatory Concepts: Basic Principles 1: Il: Innovations in Risk Assessment, Auditing and Monitoring 1: Il: Advanced Issues in Domestic and Global Transparency and Analytics \$ 595 1: IV: Advanced Global Compliances Issues \$ 595				All webcast registrants are automatically registered for the preconference and conference. Webcast conference registration includes the live Internet feed from the Congress, plus six months of continued archived Internet access, available 24/7. Preconference sessions are audio only. Mini Summit sessions will be audio streamed. STANDARD RATES:				
CONFERENCE (Does not include Preconference):				INDIVIDUAL REGISTRATION:				
☐ Through Friday, September 4, 2015* ☐ Through Friday, September 25, 2015** ☐ After Friday, September 25, 2015			,995 ,195 ,395	☐ Through Friday, September 4, 2015* \$ 795 ☐ Through Friday, September 25, 2015** \$ 995 ☐ After Friday, September 25, 2015 \$ 1,195				
GROUP REGISTRATION DISCOUNT (Does not include Preconference): Three or more registrations submitted from the same organization at the same time receive the following discounted rates for conference registration only. To qualify, all registrations must be submitted simultaneously: ☐ Through Friday, September 4, 2015* each \$1,795 ☐ Through Friday, September 25, 2015** each \$1,995				THE PHARMACEUTICAL COMPLIANCE FORUM	SPECIAL	L PHARMACEUTICAL LIANCE FORUM PCF RATES***: Preconference):		
☐ After Friday, September 25			,195	GROUP REGISTRATION:				
□ III: Advanced Issues in Do □ IV: Advanced Global Con CONFERENCE (Does not ir □ Through Friday, Septembe □ After Friday, September 25 PCF GROUP REGISTRATI FIVE OR MORE registrations the following discounted rate must be submitted simultane	asic Principles sessment, Auditing and Mon omestic and Global Transpare appliances Issues actude Preconference or Postco r 4, 2015* r 25, 2015** , 2015 ON DISCOUNTS (Does not in submitted from the same org- es for conference registration of	sitoring \$; and analytics \$; and analytics \$; and analytics \$; analytic state of the state of	495 495 495 495 695 895 095	Group registration offers the group registrants are enrol permits the organizational k colleagues or to assign and t Conference Access: See INTELLECTUAL PROPERT CONFERENCE ELECTRO Webcast attendees — Follow able on a flash drive. To take media WITH your Congress re (All webcast attendees autor	lled in the preconce of the pr	conference and confer dinator either to share conference participation 595 each	rence. Group registration conference access with on. I 20 or more \$395 each 140 or more \$295 each ontations are made availow, you must reserve + \$15 shipping) \$ 144	
-	submitted from the same orga			PAYMENT		Discount Code:		
the following discounted rates for conference registration only. To qualify, all registrations must be submitted simultaneously:				TOTAL FOR ALL OF ONSITE OR WEBCA				
Pharmaceutical Compliant each of 10 registrations:	ce Forum Group Rate/Conferer		,495	Please enclose payment with 22529 39th Ave SE, Bothell, V	your registratio			
SELECT YOUR MINI-SUMMITS — Thursday, October 22 (One from each group): BLOCK A — 11:00 am				You may also register online at www.PharmaCongress.com. Check/money order enclosed (payable to Health Care Conference Administrators LLC) Payment by credit card: American Express I wisa Mastercard If a credit card number is being given to hold registration only until such time as a check is received it must be so noted. If payment is not received by seven days prior to the Congress, the credit card payment will be processed. Credit card charges will be listed on your statement as payment to HealthCare (HC) Conf LLC. REGISTRATION BINDING AGREEMENT Registration (whether online or by this form) constitutes a contract and all of these terms and conditions are binding on the parties. In particular, these terms and conditions shall apply in the case of any credit/debit card dispute. For webcast and onsite registrants there will be no refunds for "no-shows" or cancellations.				
you must reserve media WITH your Congress registration: ☐ Flash Drive (\$129 + \$15 shipping) \$ 144 ☐ 6 months' access on Web \$ 129				ACCOUNT #				
	or registration and payment rece		2015	EXPIRATION DATE		SEC	URITY CODE	
· ·	for registration and payment rec			NAME OF CARDHOLDER				

SIGNATURE OF CARDHOLDER

*** To qualify for the PCF member rate an individual must be a employee of a member company of the Pharmaceutical Compliance Forum (PCF), www.PharmaComplianceForum.org.

Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum

Publications Printing Dept. 41651 Corporate Way Palm Desert, CA 92260 USA

(Address for Return Mail Only)

PRESORTED FIRST CLASS U.S. POSTAGE PAID PERMIT # 1 PALM DESERT, CA



www.PharmaCongress.com

THE SIXTEENTH ANNUAL

Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Transformational Learning - EFFECTIVE KNOWLEDGE EXCHANGE







